Haemonetics Announces Q1 FY26 Earnings Release and Conference Call

Haemonetics Corp will release its Q1 FY26 financial results on August 7, 2025. The company will also host a conference call at 8:00 am ET to discuss the results with investors and analysts. As a financial analyst, the announcement provides an opportunity to assess the company's financial health and operational performance. The medical technology sector is highly competitive, and timely financial disclosures can influence investor confidence and market perception.

Haemonetics Corp (NYSE: HAE) is set to release its Q1 FY26 financial results on August 7, 2025, along with a conference call at 8:00 am ET to discuss the performance with investors and analysts. The medical technology sector is highly competitive, and timely financial disclosures can significantly influence investor confidence and market perception.

As of July 2, 2025, Haemonetics Corp's stock price stands at $78.64, with a day's range of $77.60 to $79.93 and a 52-week range of $55.30 to $94.99. The company has a market capitalization of $3.8 billion, with 48.04 million shares outstanding. Analysts have a bullish sentiment, with eight analysts revising their earnings downwards for the upcoming period. The company has also been aggressively buying back shares, which could positively impact its earnings per share (EPS).

Haemonetics Corp's revenue for the past year was $1.36 billion, with net income of $167.679 million and EPS of $3.33. The company's gross profit margin is 57.2%, and its return on assets is 7.2%. The company's management has been actively participating in industry conferences, such as the Goldman Sachs 46th Annual Global Healthcare Conference, where they discussed strategic growth and challenges.

Investors and financial professionals should closely monitor the Q1 FY26 financial results and the accompanying conference call to assess the company's financial health and operational performance. The medical technology sector is highly competitive, and Haemonetics Corp's ability to maintain its market position and adapt to industry changes will be critical for its long-term success.

References:
[1] https://www.investing.com/equities/haemonetics-corp